Some women who experience menopause early-;before age 40-;have an increased risk for developing breast and ovarian cancer, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS